Related Experiment Video
Updated: Oct 6, 2026

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
Published on: November 7, 2025
Understanding PSA and prostate cancer risk assessment
1Robert Wood Johnson Medical School, New Brunswick, USA.
Abstract:
The specificity of serum PSA in screened populations is relatively low because of its inability to discern benign causes of PSA elevation from occult malignancy. An improved understanding of this widely available serum test and the availability of new modalities, such as endorectal MRI, may allow the early detection and treatment of cancer in those men who have it and may avoid unnecessary repetitive prostate biopsies in men with benign conditions.
Related Concept Videos
Cancer Survival Analysis
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Relative Risk
